^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment

Excerpt:
...genomic DNA analysis from thirteen relapsed patients revealed three known crizotinib resistance mutations, C1156Y, L1196M and G1269A.
DOI:
10.1016/j.ygeno.2013.02.006
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

Molecular resistance mechanisms of ALK inhibitors and implications for therapeutic management of ALK-rearranged lung cancer patients

Excerpt:
In this study crizotinib resistance mutations were confirmed in 11 (20%, N=51) specimens from biopsy sites that included pleural fluid (31%), liver (22%), and nodal tissue (18%) from 10 patients. L1196M and G1269A mutations represented the most common mutations with a frequency of 7% and 4% of the total mutations detected, respectively.
DOI:
10.21037/tcr.2017.03.22
Evidence Level:
Resistant: C4 – Case Studies
New
Title:

Expanded CTCs from a Patient with ALK Positive Lung Cancer Present EML4-ALK Rearrangement along with Resistance Mutation and Enable Drug Sensitivity Testing: A Case Study

Excerpt:
Whole-exome sequencing (70–100× coverage) of the biopsy revealed a secondary mutation L1196M and resultant resistance to crizotinib.
DOI:
10.1016/j.jtho.2016.07.027